U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos' Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.
About iTeos Therapeutics SA
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic ("cold") tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.
For further information, please contact:
Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
[email protected]
Amber Fennell, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
[email protected]
